Functionalised Ligand-Based Nanomaterial Drug Targeting Approaches
for Colorectal Cancer Therapy

Amol   A.   Dixit; Deepa   S.   Mandlik; Satish   K.   Mandlik
doi:10.2174/0126673878301004240703073107
Abstract

Cancer refers to a condition in which abnormal cells uncontrollably divide, resulting in the destruction of tissues. In colorectal cancer, uncontrolled cell proliferation takes place in the rectum or colon. Most colorectal tumors start as adenomas, a form of polyp that can develop into cancer within the rectum or colon. Symptoms of colorectal cancer include chronic diarrhea or constipation, bleeding from the rectum, bloody stools, change in appetite, weight loss, etc. Risk factors associated with colorectal cancer are smoking, obesity, and low physical activity. Colorectal cancer can be treated depending on size, location, and the spread of the cancer. Treatment includes surgery where the lymph node is dissected and a colectomy is performed. Chemotherapy and radiation therapies are other treatment options, but the main disadvantage is that these treatments have nonspecific avenues. Apart from killing cancerous cells, they damage healthy cells, too. Therefore, with the help of nanotechnology, drug-containing nanoparticles can be created with the aid of nanocarriers, which are stronger, more durable, and site-specific. The cancerous cells can be actively targeted by formulating nanoparticles loaded with anticancer drugs and functionalising the surface by either attaching ligands (peptides, antibodies, and small molecules) or targeting molecules towards receptors that are present on the exterior surface of the cancerous cells. These surfaces functionalised nanoparticles, loaded with anticancer drugs, are significantly upregulated in cancerous cells in contrast to healthy surrounding cells and tissues. This review article is focused on ligand-based drugs targeting colorectal tumours.
« Previous Next »
[1]
Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, Przybyłowicz KE. A review of colorectal cancer in terms of epidemiology, risk factors, development, symptoms and diagnosis. Cancers  2021; 13(9): 2025.
 [http://dx.doi.org/10.3390/cancers13092025] [PMID:  33922197]

[2]
Murphy N, Moreno V, Hughes DJ, et al. Lifestyle and dietary environmental factors in colorectal cancer susceptibility. Mol Aspects Med  2019; 69: 2-9.
 [http://dx.doi.org/10.1016/j.mam.2019.06.005] [PMID:  31233770]

[3]
Silva A, Faria G, Araújo A, Monteiro MP. Impact of adiposity on staging and prognosis of colorectal cancer. Crit Rev Oncol Hematol  2020; 145: 102857.
 [http://dx.doi.org/10.1016/j.critrevonc.2019.102857]

[4]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin  2018; 68(6): 394-424.
 [http://dx.doi.org/10.3322/caac.21492] [PMID:  30207593]

[5]
Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther  2020; 5(1): 22.
 [http://dx.doi.org/10.1038/s41392-020-0116-z] [PMID:  32296018]

[6]
Van der Stok EP, Spaander MCW, Grünhagen DJ, Verhoef C, Kuipers EJ. Surveillance after curative treatment for colorectal cancer. Nat Rev Clin Oncol  2017; 14(5): 297-315.
 [http://dx.doi.org/10.1038/nrclinonc.2016.199] [PMID:  27995949]

[7]
Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average‐risk adults: 2018 guideline update from the american cancer society. CA Cancer J Clin  2018; 68(4): 250-81.
 [http://dx.doi.org/10.3322/caac.21457] [PMID:  29846947]

[8]
Sánchez-Gundín J, Fernández-Carballido AM, Martínez-Valdivieso L, Barreda-Hernández D, Torres-Suárez AI. New trends in the therapeutic approach to metastatic colorectal cancer. Int J Med Sci  2018; 15(7): 659-65.
 [http://dx.doi.org/10.7150/ijms.24453] [PMID:  29910669]

[9]
Keum N, Giovannucci E. Global burden of colorectal cancer: Emerging trends, risk factors and prevention strategies. Nat Rev Gastroenterol Hepatol  2019; 16(12): 713-32.
 [http://dx.doi.org/10.1038/s41575-019-0189-8] [PMID:  31455888]

[10]
Khan MK, Nasti TH, Buchwald ZS, Weichselbaum RR, Kron SJ. Repurposing drugs for cancer radiotherapy. Cancer J  2019; 25(2): 106-15.
 [http://dx.doi.org/10.1097/PPO.0000000000000369] [PMID:  30896532]

[11]
Mohan G, T P AH, A J J, K M SD, Narayanasamy A, Vellingiri B. Recent advances in radiotherapy and its associated side effects in cancer—A review. J Basic Appl Zool  2019; 80(1): 14.
 [http://dx.doi.org/10.1186/s41936-019-0083-5]

[12]
Shapiro GI, Harper JW. Anticancer drug targets: Cell cycle and checkpoint control. J Clin Invest  1999; 104(12): 1645-53.

[13]
Cameron MG, Kersten C, Vistad I, Fosså S, Guren MG. Palliative pelvic radiotherapy of symptomatic incurable rectal cancer – A systematic review. Acta Oncol  2014; 53(2): 164-73.
 [http://dx.doi.org/10.3109/0284186X.2013.837582] [PMID:  24195692]

[14]
Krasteva N, Georgieva M. Promising therapeutic strategies for colorectal cancer treatment based on nanomaterials. Pharmaceutics  2022; 14(6): 1213.
 [http://dx.doi.org/10.3390/pharmaceutics14061213] [PMID:  35745786]

[15]
Belete TM. The current status of gene therapy for the treatment of cancer. Biologics  2021; 15: 67-77.
 [http://dx.doi.org/10.2147/BTT.S302095] [PMID:  33776419]

[16]
Chung-Faye GA, Kerr DJ, Young LS, Searle PF. Gene therapy strategies for colon cancer. Mol Med Today  2000; 6(2): 82-7.
 [http://dx.doi.org/10.1016/S1357-4310(99)01598-1] [PMID:  10652481]

[17]
Ziqiang Yuan, Jessica Pastoriza, Thomas Quinn, Steven K. Libutt. Targeting tumor vasculature using adeno-associated virus phage vectors coding tumor necrosis factor-α. Gene Ther Can  2014; 19-33.
 [http://dx.doi.org/10.1016/B978-0-12-394295-1.00002-0]

[18]
Hamzehzadeh L, Imanparast A, Tajbakhsh A, Rezaee M, Pasdar A. New approaches to use nanoparticles for treatment of colorectal cancer; A brief review. Nanomedicine Res J  2016; 1(2): 59-68.
 [http://dx.doi.org/10.7508/NMRJ.2016.02.001]

[19]
Subudhi M, Jain A, Jain A, et al. Eudragit S100 coated citrus pectin nanoparticles for colon targeting of 5-fluorouracil. Materials  2015; 8(3): 832-49.
 [http://dx.doi.org/10.3390/ma8030832] [PMID:  28787974]

[20]
Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev  2008; 60(15): 1615-26.
 [http://dx.doi.org/10.1016/j.addr.2008.08.005] [PMID:  18840489]

[21]
Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: A systematic review. Int J Nanomedicine  2018; 13: 3921-35.
 [http://dx.doi.org/10.2147/IJN.S165210] [PMID:  30013345]

[22]
Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers  2019; 11(5): 640.
 [http://dx.doi.org/10.3390/cancers11050640] [PMID:  31072061]

[23]
Liu Y, Hui Y, Ran R, et al. Synergetic combinations of dual-targeting ligands for enhanced in vitro and in vivo tumor targeting. Adv Healthc Mater  2018; 7(15): 1800106.
 [http://dx.doi.org/10.1002/adhm.201800106] [PMID:  29797508]

[24]
Ran R, Wang H, Liu Y, et al. Microfluidic self-assembly of a combinatorial library of single- and dual-ligand liposomes for in vitro and in vivo tumor targeting. Eur J Pharm Biopharm  2018; 130: 1-10.
 [http://dx.doi.org/10.1016/j.ejpb.2018.06.017] [PMID:  29908938]

[25]
U. S. national institutes of health, national cancer institute. 2021. Available from: https://www.cancer.gov/about-cancer/diagnosisstaging/diagnosis/tumor-markers[Accessed May 15, 2023]

[26]
De Assis JV, Coutinho LA, Oyeyemi IT, Oyeyemi OT, Grenfell RFEQ. Diagnostic and therapeutic biomarkers in colorectal cancer: A review. Am J Cancer Res  2022; 12(2): 661-80.
 [PMID:  35261794]

[27]
Tiernan JP, Perry SL, Verghese ET, et al. Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting. Br J Cancer  2013; 108(3): 662-7.
 [http://dx.doi.org/10.1038/bjc.2012.605] [PMID:  23322207]

[28]
Jelski W, Mroczko B. Biochemical markers of colorectal cancer – Present and future. Cancer Manag Res  2020; 12: 4789-97.
 [http://dx.doi.org/10.2147/CMAR.S253369] [PMID:  32606968]

[29]
Guadagni F, Roselli M, Cosimelli M, et al. TAG-72 (CA 72-4 assay) as a complementary serum tumor antigen to carcinoembryonic antigen in monitoring patients with colorectal cancer. Cancer  1993; 72(7): 2098-106.
 [http://dx.doi.org/10.1002/1097-0142(19931001)72:7<2098::AID-CNCR2820720707>3.0.CO;2-G] [PMID:  8374868]

[30]
Manzi J, Hoff CO, Ferreira R, et al. Targeted therapies in colorectal cancer: Recent advances in biomarkers, landmark trials, and future perspectives. Cancers  2023; 15(11): 3023.
 [http://dx.doi.org/10.3390/cancers15113023] [PMID:  37296986]

[31]
Colicelli J. Human RAS superfamily proteins and related GTPases. Sci STKE  2004; 2004(250): RE13.
 [http://dx.doi.org/10.1126/stke.2502004re13] [PMID: 15367757]

[32]
Tougeron D, Laurent-Puig P, Zaanan A. Comment on ‘KRASmutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’. Br J Cancer  2014; 111(12): 2379-80.
 [http://dx.doi.org/10.1038/bjc.2014.114] [PMID:  24619075]

[33]
Suzuki S, Yonesaka K, Teramura T, et al. KRAS inhibitor-resistance in MET-amplified KRASG12C non-small cell lung cancer induced by RAS- And non-RAS-mediated cell signaling mechanisms. Clin Cancer Res  2021; 27(20): 5697-707.
 [http://dx.doi.org/10.1158/1078-0432.CCR-21-0856] [PMID:  34365406]

[34]
Bradley CA, Dunne PD, Bingham V, et al. Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer. Oncotarget  2016; 7(48): 78932-45.
 [http://dx.doi.org/10.18632/oncotarget.12933] [PMID:  27793046]

[35]
Schmid D, Fay F, Small DM, et al. Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine. Mol Ther  2014; 22(12): 2083-92.
 [http://dx.doi.org/10.1038/mt.2014.137] [PMID:  25200008]

[36]
Hasan MR, Ho SHY, Owen DA, Tai IT. Inhibition of VEGF induces cellular senescence in colorectal cancer cells. Int J Cancer  2011; 129(9): 2115-23.
 [http://dx.doi.org/10.1002/ijc.26179] [PMID:  21618508]

[37]
Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol  2019; 71(8): 1185-98.
 [http://dx.doi.org/10.1111/jphp.13098] [PMID:  31049986]

[38]
Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater  2021; 6(4): 351-70.
 [http://dx.doi.org/10.1038/s41578-020-00269-6] [PMID:  34950512]

[39]
Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev  2018; 130: 17-38.
 [http://dx.doi.org/10.1016/j.addr.2018.07.007] [PMID:  30009886]

[40]
Subhan MA, Yalamarty SSK, Filipczak N, Parveen F, Torchilin VP. Recent advances in tumor targeting via epr effect for cancer treatment. J Pers Med  2021; 11(6): 571.
 [http://dx.doi.org/10.3390/jpm11060571] [PMID:  34207137]

[41]
Lee SY, Yang CY, Peng CL, et al. A theranostic micelleplex codelivering SN-38 and VEGF siRNA for colorectal cancer therapy. Biomaterials  2016; 86: 92-105.
 [http://dx.doi.org/10.1016/j.biomaterials.2016.01.068] [PMID:  26896610]

[42]
Morales-Cruz M, Delgado Y, Castillo B, et al. Smart targeting to improve cancer therapeutics. Drug Des Devel Ther  2019; 13: 3753-72.
 [http://dx.doi.org/10.2147/DDDT.S219489] [PMID:  31802849]

[43]
Riaz M, Riaz M, Zhang X, et al. Surface functionalization and targeting strategies of liposomes in solid tumor therapy: A review. Int J Mol Sci  2018; 19(1): 195.
 [http://dx.doi.org/10.3390/ijms19010195] [PMID:  29315231]

[44]
Zhao Y, Xu J, Le VM, et al. EpCAM aptamer-functionalized cationic liposome-based nanoparticles loaded with mir-139-5p for targeted therapy in colorectal cancer. Mol Pharm  2019; 16(11): 4696-710.
 [http://dx.doi.org/10.1021/acs.molpharmaceut.9b00867] [PMID:  31589818]

[45]
Xiao B, Han MK, Viennois E, et al. Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy. Nanoscale  2015; 7(42): 17745-55.
 [http://dx.doi.org/10.1039/C5NR04831A] [PMID:  26455329]

[46]
Ning ST, Lee SY, Wei MF, et al. Targeting colorectal cancer stem-like cells with anti-cd133 antibody-conjugated sn-38 nanoparticles. ACS Appl Mater Interfaces  2016; 8(28): 17793-804.
 [http://dx.doi.org/10.1021/acsami.6b04403]

[47]
Mojarad-Jabali S, Farshbaf M, Walker PR, et al. An update on actively targeted liposomes in advanced drug delivery to glioma. Int J Pharm  2021; 602: 120645.
 [http://dx.doi.org/10.1016/j.ijpharm.2021.120645] [PMID:  33915182]

[48]
Lima PHC, Butera AP, Cabeça LF, Ribeiro-Viana RM. Liposome surface modification by phospholipid chemical reactions. Chem Phys Lipids  2021; 237: 105084.
 [http://dx.doi.org/10.1016/j.chemphyslip.2021.105084] [PMID:  33891960]

[49]
Moghimipour E, Rezaei M, Ramezani Z, et al. Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil. Eur J Pharm Sci  2018; 114: 166-74.
 [http://dx.doi.org/10.1016/j.ejps.2017.12.011] [PMID:  29247686]

[50]
Khayrani AC, Mahmud H, Oo AKK, et al. Targeting ovarian cancer cells overexpressing CD44 with immunoliposomes encap-sulating glycosylated paclitaxel. Int J Mol Sci  2019; 20(5): 1042.
 [http://dx.doi.org/10.3390/ijms20051042] [PMID:  30818864]

[51]
Shim G, Kim D, Lee S, Chang RS, Byun J, Oh YK. Staphylococcus aureus-mimetic control of antibody orientation on nanoparticles. Nanomedicine  2019; 16: 267-77.
 [http://dx.doi.org/10.1016/j.nano.2018.09.007] [PMID:  30368001]

[52]
Zhang Y, He J, Shen L, et al. Brain-targeted delivery of obidoxime, using aptamer-modified liposomes, for detoxification of organophosphorus compounds. J Control Release  2021; 329: 1117-28.
 [http://dx.doi.org/10.1016/j.jconrel.2020.10.039] [PMID:  33096123]

[53]
Li T, Yu P, Chen Y, et al. N-acetylgalactosamine-decorated nanoliposomes for targeted delivery of paclitaxel to hepatocellular carcinoma. Eur J Med Chem  2021; 222: 113605.
 [http://dx.doi.org/10.1016/j.ejmech.2021.113605] [PMID:  34126457]

[54]
Wöll S, Dickgiesser S, Rasche N, Schiller S, Scherließ R. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells. Eur J Pharm Biopharm  2019; 136: 203-12.
 [http://dx.doi.org/10.1016/j.ejpb.2019.01.020] [PMID:  30677497]

[55]
Khaleseh F, Hemmati Azandaryani A, Fathian Kolahkaj F, Khazaei M, Derakhshandeh K. Enhancement of in vitro anti-tumour activity of epirubicin in HER2+ breast cancer cells using immunoliposome formulation. IET Nanobiotechnol  2021; 15(3): 257-65.
 [http://dx.doi.org/10.1049/nbt2.12012] [PMID:  34694666]

[56]
Yue G, Wang C, Liu B, et al. Liposomes co-delivery system of doxorubicin and astragaloside IV co-modified by folate ligand and octa-arginine polypeptide for anti-breast cancer. RSC Advances  2020; 10(20): 11573-81.
 [http://dx.doi.org/10.1039/C9RA09040A] [PMID:  35496626]

[57]
Ding J, Sui D, Liu M, et al. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy. 2021; 134: 702-15.
 [http://dx.doi.org/10.1016/j.actbio.2021.07.063]

[58]
Allen TM, Sapra P, Moase E. Use of the post-insertion method for the formation of ligand-coupled liposomes. Cell Mol Biol Lett  2002; 7(3): 889-94.
 [PMID:  12378272]

[59]
Shahraki N, Mehrabian A, Amiri-Darban S, Moosavian SA, Jaafari MR. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma. Colloids Surf B Biointerfaces  2021; 200: 111589.
 [http://dx.doi.org/10.1016/j.colsurfb.2021.111589] [PMID:  33545570]

[60]
Burgus R, Ling N, Butcher M, Guillemin R. Primary structure of somatostatin, a hypothalamic peptide that inhibits the secretion of pituitary growth hormone. Proc Natl Acad Sci USA  1973; 70(3): 684-8.
 [http://dx.doi.org/10.1073/pnas.70.3.684] [PMID:  4514982]

[61]
Pless J, Bauer W, Briner U, et al. Chemistry and pharmacology of SMS 201-995, a long-acting octapeptide analogue of somatostatin. Scand J Gastroenterol Suppl  1986; 119: 54-64.
 [http://dx.doi.org/10.3109/00365528609087432]

[62]
Jiang Z, Guan J, Qian J, Zhan C. Peptide ligand-mediated targeted drug delivery of nanomedicines. Biomater Sci  2019; 7(2): 461-71.
 [http://dx.doi.org/10.1039/C8BM01340C] [PMID:  30656305]

[63]
Ayiomamitis GD, Notas G, Zaravinos A, et al. Effects of octreotide and insulin on colon cancer cellular proliferation and correlation with hTERT activity. Oncoscience  2014; 1(6): 457-67.
 [http://dx.doi.org/10.18632/oncoscience.58] [PMID:  25594044]

[64]
Fogal V, Zhang L, Krajewski S, Ruoslahti E. Mitochondrial/cellsurface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res  2008; 68(17): 7210-8.
 [http://dx.doi.org/10.1158/0008-5472.CAN-07-6752] [PMID:  18757437]

[65]
Marasini R, Nguyen TDT, Rayamajhi S, Aryal S. Synthesis and characterization of a tumor-seeking LyP-1 peptide integrated lipid–polymer composite nanoparticle. Ma Adv  2020; 1(3): 469-80.
 [http://dx.doi.org/10.1039/D0MA00203H]

[66]
Song N, Zhao L, Zhu M, Zhao J. Recent progress in LyP-1-based strategies for targeted imaging and therapy. Drug Deliv  2019; 26(1): 363-75.
 [http://dx.doi.org/10.1080/10717544.2019.1587047] [PMID:  30905205]

[67]
Biscaglia F, Ripani G, Rajendran S, et al. Gold nanoparticle aggregates functionalized with cyclic rgd peptides for targeting and imaging of colorectal cancer cells. ACS Appl Nano Mater  2019; 2(10): 6436-44.
 [http://dx.doi.org/10.1021/acsanm.9b01392]

[68]
Danhier F, Le Breton A, Préat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm  2012; 9(11): 2961-73.
 [http://dx.doi.org/10.1021/mp3002733] [PMID:  22967287]

[69]
Yao P, Wang X, Wang Q, et al. Cyclic rgd-functionalized ph/ros dual-responsive nanoparticle for targeted breast cancer therapy. Pharmaceutics  2023; 15(7): 1827.
 [http://dx.doi.org/10.3390/pharmaceutics15071827] [PMID:  37514014]

[70]
Prutki M, Poljak-Blazi M, Jakopovic M, Tomas D, Stipancic I, Zarkovic N. Altered iron metabolism, transferrin receptor 1 and ferritin in patients with colon cancer. Cancer Lett  2006; 238(2): 188-96.
 [http://dx.doi.org/10.1016/j.canlet.2005.07.001] [PMID:  16111806]

[71]
Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P. Transferrin receptor 1 in cancer: A new sight for cancer therapy. Am J Cancer Res  2018; 8(6): 916-31.
 [PMID:  30034931]

[72]
Mendelsohn J, Prewett M, Rockwell P, Goldstein NI. CCR 20th anniversary commentary: A chimeric antibody, C225, inhibits EGFR activation and tumor growth. Clin Cancer Res  2015; 21(2): 227-9.
 [http://dx.doi.org/10.1158/1078-0432.CCR-14-2491] [PMID:  25593342]

[73]
Morgillo F, Cantile F, Fasano M, Troiani T, Martinelli E, Ciardiello F. Resistance mechanisms of tumour cells to EGFR inhibitors. Clin Transl Oncol  2009; 11(5): 270-5.
 [http://dx.doi.org/10.1007/s12094-009-0354-6] [PMID:  19451059]

[74]
Sakthianandeswaren A, Sabljak P, Elliott MJ, Palmieri MM, Sieber O. Predictive biomarkers for monoclonal antibody therapies targeting EGFR (Cetuximab, Panitumumab) in the treatment of metastatic colorectal cancer. In: Advances in the molecular understanding of colorectal cancer. IntechOpen 2019.
 [http://dx.doi.org/10.5772/intechopen.80690]

[75]
Misra S, Hascall VC, de Giovanni C, Markwald RR, Ghatak S. Delivery of CD44 shRNA/nanoparticles within cancer cells: Perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J Biol Chem  2009; 284(18): 12432-46.
 [http://dx.doi.org/10.1074/jbc.M806772200] [PMID:  19246453]

[76]
Makkar S, Riehl TE, Chen B, et al. Hyaluronic acid binding to TLR4 promotes proliferation and blocks apoptosis in colon cancer. Mol Cancer Ther  2019; 18(12): 2446-56.
 [http://dx.doi.org/10.1158/1535-7163.MCT-18-1225] [PMID:  31484704]

[77]
Fitzgerald KA, Malhotra M, Gooding M, et al. A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor. Int J Pharm  2016; 499(1-2): 131-45.
 [http://dx.doi.org/10.1016/j.ijpharm.2015.12.055] [PMID:  26721726]

[78]
Dasargyri A, Kümin CD, Leroux JC. Targeting nanocarriers with anisamide: Fact or artifact? Adv Mater  2017; 29(7): 1603451.
 [http://dx.doi.org/10.1002/adma.201603451] [PMID:  27885719]

[79]
van Waarde A, Rybczynska AA, Ramakrishnan NK, Ishiwata K, Elsinga PH, Dierckx RAJO. Potential applications for sigma receptor ligands in cancer diagnosis and therapy.  In: Elsevier B.V. 2015; 1848.
 [http://dx.doi.org/10.1016/j.bbamem.2014.08.022]

[80]
Gothwal A, Malik S, Gupta U, Jain NK. Toxicity and biocompatibility aspects of dendrimers. In: Elsevier Inc. 2019.
 [http://dx.doi.org/10.1016/B978-0-12-814527-2.00011-1]

[81]
van Dam GM, Themelis G, Crane LMA, et al. Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: First in-human results. Nat Med  2011; 17(10): 1315-9.
 [http://dx.doi.org/10.1038/nm.2472] [PMID:  21926976]

[82]
Hu Y, Duan J, Zhan Q, Wang F, Lu X, Yang XD. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One  2012; 7(2): e31970.
 [http://dx.doi.org/10.1371/journal.pone.0031970] [PMID:  22384115]

[83]
Ghasemi Z, Dinarvand R, Mottaghitalab F, Esfandyari-Manesh M, Sayari E, Atyabi F. Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. Carbohydr Polym  2015; 121: 190-8.
 [http://dx.doi.org/10.1016/j.carbpol.2014.12.025] [PMID:  25659689]

[84]
Chen K, Conti PS. Target-specific delivery of peptide-based probes for PET imaging. Adv Drug Deliv Rev  2010; 62(11): 1005-22.
 [http://dx.doi.org/10.1016/j.addr.2010.09.004] [PMID:  20851156]

[85]
Ayo A, Laakkonen P. Peptide-based strategies for targeted tumor treatment and imaging. Pharmaceutics  2021; 13(4): 481.
 [http://dx.doi.org/10.3390/pharmaceutics13040481] [PMID:  33918106]

[86]
Itatani Y, Kawada K, Sakai Y. Transforming growth factor-β signaling pathway in colorectal cancer and its tumor microenvironment. Int J Mol Sci  2019; 20(23): 5822.
 [http://dx.doi.org/10.3390/ijms20235822] [PMID:  31756952]

[87]
Worm DJ, Els-Heindl S, Beck-Sickinger AG. Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. Pept Sci (Hoboken)  2020; 112(3): e24171.
 [http://dx.doi.org/10.1002/pep2.24171]

[88]
Kratz F. Drug conjugates with albumin and transferrin. Expert Opin Ther Pat  2002; 12(3): 433-9.
 [http://dx.doi.org/10.1517/13543776.12.3.433]

[89]
Accardo, A., Tesauro, D. & Morelli, G. Peptide-based targeting strategies for simultaneous imaging and therapy with nanovectors. Polym J  2013; 45: 481-93.
 [http://dx.doi.org/10.1038/pj.2012.215]

[90]
Terashima M, Uchida M, Kosuge H, et al. Protein cage nanoparticles bearing the lyp-1 peptide for enhanced imaging of macrophagerich vascular lesions masaki. ACS Nano  2012; 32(5): 1430-7.
 [http://dx.doi.org/10.1038/nm720]

[91]
D’Souza SE, Ginsberg MH, Plow EF. Arginyl-glycyl-aspartic acid (RGD): A cell adhesion motif. Trends Biochem Sci  1991; 16(7): 246-50.
 [http://dx.doi.org/10.1016/0968-0004(91)90096-E] [PMID:  1926332]

[92]
Bao H, Zheng N, Li Z, Zhi Y. Synergistic effect of tangeretin and atorvastatin for colon cancer combination therapy: Targeted delivery of these dual drugs using RGD peptide decorated nanocarriers. Drug Des Devel Ther  2020; 14: 3057-68.
 [http://dx.doi.org/10.2147/DDDT.S256636] [PMID:  32801644]

[93]
Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta, Gen Subj  2012; 1820(3): 291-317.
 [http://dx.doi.org/10.1016/j.bbagen.2011.07.016] [PMID:  21851850]

[94]
Wei Y, Gu X, Sun Y, Meng F, Storm G, Zhong Z. Transferrinbinding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo. J Control Release  2020; 319(319): 407-15.
 [http://dx.doi.org/10.1016/j.jconrel.2020.01.012] [PMID:  31923538]

[95]
Ishida O, Maruyama K, Tanahashi H, et al. Transferrin with intracellular tumors in vivo. In: In Vivo.  Brooklyn 2001; 18: pp. (7)1042-8.

[96]
Salahpour Anarjan F. Active targeting drug delivery nanocarriers: Ligands. Nano-Structures & Nano-Objects  2019; 19: 100370.
 [http://dx.doi.org/10.1016/j.nanoso.2019.100370]

[97]
Sultana S, Khan MR, Kumar M, Kumar S, Ali M. Nanoparticlesmediated drug delivery approaches for cancer targeting: A review. J Drug Target  2013; 21(2): 107-25.
 [http://dx.doi.org/10.3109/1061186X.2012.712130] [PMID:  22873288]

[98]
Alibakhshi A, Abarghooi Kahaki F, Ahangarzadeh S, et al. Targeted cancer therapy through antibody fragments-decorated nanomedicines. J Control Release  2017; 268: 323-34.
 [http://dx.doi.org/10.1016/j.jconrel.2017.10.036] [PMID:  29107128]

[99]
Richards DA, Maruani A, Chudasama V. Antibody fragments as nanoparticle targeting ligands: A step in the right direction. Chem Sci  2017; 8(1): 63-77.
 [http://dx.doi.org/10.1039/C6SC02403C] [PMID:  28451149]

[100]
Tian Y, Hu D, Li Y, Yang L. Development of therapeutic vaccines for the treatment of diseases. Molecular Biomedicine  2022; 3(1): 40.
 [http://dx.doi.org/10.1186/s43556-022-00098-9] [PMID:  36477638]

[101]
Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit Rev Oncol Hematol  2005; 54(1): 11-29.
 [http://dx.doi.org/10.1016/j.critrevonc.2004.10.011] [PMID:  15780905]

[102]
Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature  1975; 256(5517): 495-7.
 [http://dx.doi.org/10.1038/256495a0] [PMID:  1172191]

[103]
Veronese ML, O’Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer  2004; 40(9): 1292-301.
 [http://dx.doi.org/10.1016/j.ejca.2004.02.014] [PMID:  15177487]

[104]
Brüggemann M, Winter G, Waldmann H, Neuberger MS. The immunogenicity of chimeric antibodies. J Exp Med  1989; 170(6): 2153-7.
 [http://dx.doi.org/10.1084/jem.170.6.2153] [PMID:  2584938]

[105]
Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med  2004; 351(4): 337-45.
 [http://dx.doi.org/10.1056/NEJMoa033025] [PMID:  15269313]

[106]
Hudson PJ, Souriau C. Engineered antibodies. Nat Med  2003; 9(1): 129-34.
 [http://dx.doi.org/10.1038/nm0103-129] [PMID:  12514726]

[107]
Keating GM. Panitumumab. Drugs  2010; 70(8): 1059-78.
 [http://dx.doi.org/10.2165/11205090-000000000-00000] [PMID: 20481659]

[108]
Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: A systematic review. Int J Nanomedicine  2018; 13: 3921-35.
 [http://dx.doi.org/10.2147/IJN.S165210]

[109]
Ramzy L, Metwally AA, Nasr M, Awad GAS. Novel thymoquinone lipidic core nanocapsules with anisamide-polymethacrylate shell for colon cancer cells overexpressing sigma receptors. Sci Rep  2020; 10(1): 10987.
 [http://dx.doi.org/10.1038/s41598-020-67748-2] [PMID:  32620860]

[110]
Sirisha VL, D’Souza JS. Polysaccharide-based nanoparticles as drug delivery systems.  Marine OMICS 2016; pp. 663-702.

[111]
Garcia-Valdez O, Champagne P, Cunningham MF. Graft modification of natural polysaccharides via reversible deactivation radical polymerization. Prog Polym Sci  2018; 76: 151-73.
 [http://dx.doi.org/10.1016/j.progpolymsci.2017.08.001]

[112]
Madni A, Tahir N, Rehman M, et al. Hybrid nano-carriers for potential drug delivery. Advanced technology for delivering therapeutics  2017; 11: 54-87.
 [http://dx.doi.org/10.5772/66466]

[113]
Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell  1990; 61(7): 1303-13.
 [http://dx.doi.org/10.1016/0092-8674(90)90694-A] [PMID:  1694723]

[114]
Sherman L, Sleeman J, Herrlich P, Ponta H. Hyaluronate receptors: Key players in growth, differentiation, migration and tumor progression. Curr Opin Cell Biol  1994; 6(5): 726-33.
 [http://dx.doi.org/10.1016/0955-0674(94)90100-7] [PMID:  7530464]

[115]
Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by toll-like receptors and hyaluronan. Nat Med  2005; 11(11): 1173-9.
 [http://dx.doi.org/10.1038/nm1315] [PMID:  16244651]

[116]
Fan X, Wang T, Han M, et al. Dual CEA/CD44 targeting to colorectal cancer cells using nanobody-conjugated hyaluronic acidmodified mesoporous silica nanoparticles with pH-and redox-sensitivity. Materials Advances  2022; 3(11): 4707-17.
 [http://dx.doi.org/10.1039/D2MA00082B]

[117]
Wang Z, Zang A, Wei Y, et al. Hyaluronic acid capped, irinotecan and gene co-loaded lipid-polymer hybrid nanocarrier-based combination therapy platform for colorectal cancer. Drug Des Devel Ther  2020; 14: 1095-105.
 [http://dx.doi.org/10.2147/DDDT.S230306] [PMID:  32210538]

[118]
Pan DC, Krishnan V, Salinas AK, et al. Hyaluronic a cid– doxorubicin nanoparticles for targeted treatment of colorectal cancer. Bioeng Transl Med  2021; 6(1): e10166.
 [http://dx.doi.org/10.1002/btm2.10166] [PMID:  33532580]

[119]
Liu K, Wang ZQ, Wang SJ, et al. Hyaluronic acid-tagged silica nanoparticles in colon cancer therapy: Therapeutic efficacy evaluation. Int J Nanomed  2015; 10: 6445-54.
 [http://dx.doi.org/10.2147/IJN.S89476]

[120]
Nogueira E, Gomes AC, Preto A, Cavaco-Paulo A. Folate-targeted nanoparticles for rheumatoid arthritis therapy. Nanomedicine  2016; 12(4): 1113-26.
 [http://dx.doi.org/10.1016/j.nano.2015.12.365] [PMID:  26733257]

[121]
Song Y, Shi W, Chen W, Li X, Ma H. Fluorescent carbon nanodots conjugated with folic acid for distinguishing folate-receptorpositive cancer cells from normal cells. J Mater Chem  2012; 22(25): 12568-73.
 [http://dx.doi.org/10.1039/c2jm31582c]

[122]
Wang S, Low PS. Folate-mediated targeting of antineoplastic drugs, imaging agents, and nucleic acids to cancer cells. J Control Release  1998; 53(1-3): 39-48.
 [http://dx.doi.org/10.1016/S0168-3659(97)00236-8] [PMID:  9741912]

[123]
El-Hammadi MM, Delgado ÁV, Melguizo C, Prados JC, Arias JL. Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. Int J Pharm  2017; 516(1-2): 61-70.
 [http://dx.doi.org/10.1016/j.ijpharm.2016.11.012] [PMID:  27825867]

[124]
Zou Y, Xiao F, Song L, et al. A folate-targeted PEGylated cyclodextrin-based nanoformulation achieves co-delivery of docetaxel and siRNA for colorectal cancer. Int J Pharm  2021; 606: 120888.
 [http://dx.doi.org/10.1016/j.ijpharm.2021.120888] [PMID:  34271152]

[125]
Mirzaghavami PS, Khoei S, Khoee S, Shirvalilou S. Folic acidconjugated magnetic triblock copolymer nanoparticles for dual targeted delivery of 5-fluorouracil to colon cancer cells. Cancer Nanotechnol  2022; 13(1): 12.
 [http://dx.doi.org/10.1186/s12645-022-00120-3]

[126]
Duo Y, Yang M, Du Z, et al. CX-5461-loaded nucleolus-targeting nanoplatform for cancer therapy through induction of pro-death autophagy. Acta Biomater  2018; 79: 317-30.
 [http://dx.doi.org/10.1016/j.actbio.2018.08.035] [PMID:  30172068]

[127]
Tombelli S, Minunni M, Mascini M. Analytical applications of aptamers. Biosens Bioelectron  2005; 20(12): 2424-34.
 [http://dx.doi.org/10.1016/j.bios.2004.11.006] [PMID:  15854817]

[128]
Iliuk AB, Hu L, Tao WA. Aptamer in bioanalytical applications. Anal Chem  2011; 83(12): 4440-52.
 [http://dx.doi.org/10.1021/ac201057w] [PMID:  21524128]

[129]
Chen T, Shukoor MI, Chen Y, et al. Aptamer-conjugated nanomaterials for bioanalysis and biotechnology applications. Nanoscale  2011; 3(2): 546-56.
 [http://dx.doi.org/10.1039/C0NR00646G] [PMID:  21109879]

[130]
Tan W, Donovan MJ, Jiang J. Aptamers from cell-based selection for bioanalytical applications. Chem Rev  2013; 113(4): 2842-62.
 [http://dx.doi.org/10.1021/cr300468w] [PMID:  23509854]

[131]
Zhang L, Radovic-Moreno AF, Alexis F, et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem  2007; 2(9): 1268-71.
 [http://dx.doi.org/10.1002/cmdc.200700121] [PMID:  17600796]

[132]
Tong GJ, Hsiao SC, Carrico ZM, Francis MB. Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J Am Chem Soc  2009; 131(31): 11174-8.
 [http://dx.doi.org/10.1021/ja903857f] [PMID:  19603808]

[133]
Yang L, Zhang X, Ye M, et al. Aptamer-conjugated nanomaterials and their applications. Adv Drug Deliv Rev  2011; 63(14-15): 1361-70.
 [http://dx.doi.org/10.1016/j.addr.2011.10.002] [PMID:  22016112]

[134]
Xiao Z, Farokhzad OC. Aptamer-functionalized nanoparticles for medical applications: Challenges and opportunities. ACS Nano  2012; 6(5): 3670-6.
 [http://dx.doi.org/10.1021/nn301869z] [PMID:  22574989]

[135]
Xing H, Tang L, Yang X, et al. Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo. J Mater Chem B Mater Biol Med  2013; 1(39): 5288-97.
 [http://dx.doi.org/10.1039/c3tb20412j] [PMID:  24159374]

[136]
Hu Y, Duan J, Zhan Q, Wang F, Lu X, Yang X Da. Novel muc1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One  2012; 7(2): e31970.
 [http://dx.doi.org/10.1371/journal.pone.0031970]

[137]
Wöll S, Dickgiesser S, Rasche N, Schiller S, Scherließ R. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells. Eur J Pharm Biopharm  2019; 136: 203-12.
 [http://dx.doi.org/10.1016/j.ejpb.2019.01.020.]

[138]
Dubrovskaya V, Tran K, Ozorowski G, et al. Vaccination with glycan-modified hiv nfl envelope trimer-liposomes elicits broadly neutralizing antibodies to multiple sites of vulnerability. Immunity  2019; 51(5): 915-929.e7.
 [http://dx.doi.org/10.1016/j.immuni.2019.10.008] [PMID:  31732167]

[139]
Takayama Y, Kusamori K, Tsukimori C, et al. Anticancer drugloaded mesenchymal stem cells for targeted cancer therapy. J Control Release  2021; 329: 1090-101.
 [http://dx.doi.org/10.1016/j.jconrel.2020.10.037] [PMID:  33098911]

[140]
Hirata Y, Tashima R, Mitsuhashi N, et al. A simple, fast, and orientation-controllable technology for preparing antibody-modified liposomes. Int J Pharm  2021; 607: 120966.
 [http://dx.doi.org/10.1016/j.ijpharm.2021.120966] [PMID:  34352337]

[141]
Dos Santos Rodrigues B, Banerjee A, Kanekiyo T, Singh J. Functionalized liposomal nanoparticles for efficient gene delivery system to neuronal cell transfection. Int J Pharm  2019; 566: 717-30.
 [http://dx.doi.org/10.1016/j.ijpharm.2019.06.026] [PMID:  31202901]

[142]
Kang S, Duan W, Zhang S, Chen D, Feng J, Qi N. Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma. Theranostics  2020; 10(10): 4308-22.
 [http://dx.doi.org/10.7150/thno.41322] [PMID:  32292496]

[143]
Narayanaswamy R, Torchilin VP. Targeted delivery of combination therapeutics using monoclonal antibody 2c5-modified immunoliposomes for cancer therapy. Pharm Res  2021; 38(3): 429-50.
 [http://dx.doi.org/10.1007/s11095-021-02986-1] [PMID:  33655395]

[144]
Lee J, Byun J, Shim G, Oh YK. Fibroblast activation protein activated antifibrotic peptide delivery attenuates fibrosis in mouse models of liver fibrosis. Nat Commun  2022; 13(1): 1516.
 [http://dx.doi.org/10.1038/s41467-022-29186-8] [PMID:  35314685]

[145]
Lee SH, Sato Y, Hyodo M, Harashima H. Size-dependency of the surface ligand density of liposomes prepared by post-insertion. Biol Pharm Bull  2017; 40(7): 1002-9.
 [http://dx.doi.org/10.1248/bpb.b16-00990] [PMID:  28674243]

[146]
Chen C, Zhou Y, Chen C, Zhu S, Yan X. Quantification of available ligand density on the surface of targeted liposomal nanomedicines at the single-particle level. ACS Nano  2022; 16(4): 6886-97.
 [http://dx.doi.org/10.1021/acsnano.2c02084] [PMID:  35394292]

[147]
Shim G, Kim D, Lee S, Chang RS, Byun J, Oh YK. Staphylococcus aureus-mimetic control of antibody orientation on nanoparticles. Nanomed Nanotechnol Biol Med  2019; 16: 267-77.
 [http://dx.doi.org/10.1016/j.nano.2018.09.007]

[148]
Modery-Pawlowski CL, Sen Gupta A. Heteromultivalent liganddecoration for actively targeted nanomedicine. Biomaterials  2014; 35(9): 2568-79.
 [http://dx.doi.org/10.1016/j.biomaterials.2013.12.047] [PMID: 24411677]

[149]
Di Iorio D, Huskens J. Surface modification with control over ligand density for the study of multivalent biological systems. ChemistryOpen  2020; 9(1): 53-66.
 [http://dx.doi.org/10.1002/open.201900290] [PMID:  31921546]

[150]
Xu L, Josan JS, Vagner J, et al. Heterobivalent ligands target cellsurface receptor combinations in vivo. Proc Natl Acad Sci USA  2012; 109(52): 21295-300.
 [http://dx.doi.org/10.1073/pnas.1211762109] [PMID:  23236171]

[151]
Bannigan P, Aldeghi M, Bao Z, Häse F, Aspuru-Guzik A, Allen C. Machine learning directed drug formulation development. Adv Drug Deliv Rev  2021; 175: 113806.
 [http://dx.doi.org/10.1016/j.addr.2021.05.016] [PMID:  34019959]

[152]
Macarron R, Banks MN, Bojanic D, et al. Impact of highthroughput screening in biomedical research. Nat Rev Drug Discov  2011; 10(3): 188-95.
 [http://dx.doi.org/10.1038/nrd3368] [PMID:  21358738]

[153]
Kumar R, Le N, Tan Z, Brown ME, Jiang S, Reineke TM. Efficient polymer-mediated delivery of gene-editing ribonucleoprotein payloads through combinatorial design, parallelized experimentation, and machine learning. ACS Nano  2020; 14(12): 17626-39.
 [http://dx.doi.org/10.1021/acsnano.0c08549] [PMID:  33225680]

[154]
Rinkenauer AC, Vollrath A, Schallon A, et al. Parallel highthroughput screening of polymer vectors for nonviral gene delivery: Evaluation of structure-property relationships of transfection. ACS Comb Sci  2013; 15(9): 475-82.
 [http://dx.doi.org/10.1021/co400025u] [PMID:  23886244]

[155]
Stavnsbjerg C. Accelerated blood clearance and hypersensitivity by PEGylated liposomes containing TLR agonists. J Contr Release  2022; 342(2022): 337-44.

[156]
Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater  2021; 6(12): 1078-94.
 [http://dx.doi.org/10.1038/s41578-021-00358-0] [PMID:  34394960]

[157]
Ball RL. Achieving long-term stability of lipid nanoparticles: Examining the effect of pH, temperature, and lyophilization. Int J Nanomed  2017; 12: 305-15.

[158]
Jain A, Jain R, Jain S, Khatik R, Veer Kohli D. Minicapsules encapsulating nanoparticles for targeting, apoptosis induction and treatment of colon cancer. Artif Cells Nanomed Biotechnol  2019; 47(1): 1085-93.
 [http://dx.doi.org/10.1080/21691401.2019.1593848] [PMID:  30942626]

[159]
Sesarman A, Tefas L, Sylvester B, et al. Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment. Drug Deliv Transl Res  2019; 9(1): 260-72.
 [http://dx.doi.org/10.1007/s13346-018-00598-8] [PMID:  30421392]

[160]
Shi H, Liang GF, Li Y, et al. Preparation and evaluation of upconversion nanoparticles based miRNA delivery carrier in colon cancer mice model. J Biomed Nanotechnol  2019; 15(11): 2240-50.
 [http://dx.doi.org/10.1166/jbn.2019.2840] [PMID:  31847938]

[161]
Zhong Y, Su T, Shi Q, et al. Co-Administration of irgd enhances tumor-targeted delivery and anti-tumor effects of paclitaxel-loaded plga nanoparticles for colorectal cancer treatment. Int J Nanomedicine  2019; 14: 8543-60.
 [http://dx.doi.org/10.2147/IJN.S219820] [PMID:  31802868]

[162]
Zhang X, Zhao M, Cao N, et al. Construction of a tumor microenvironment pH-responsive cleavable PEGylated hyaluronic acid nano-drug delivery system for colorectal cancer treatment. Biomater Sci  2020; 8(7): 1885-96.
 [http://dx.doi.org/10.1039/C9BM01927H] [PMID:  32022813]

[163]
Wei Y, Gu X, Sun Y, Meng F, Storm G, Zhong Z. Transferrinbinding peptide functionalized polymersomes mediate targeted doxorubicin delivery to colorectal cancer in vivo. J Control Release  2020; 319: 407-15.
 [http://dx.doi.org/10.1016/j.jconrel.2020.01.012]

[164]
Chibaudel B, Maindrault-Goebel F, Bachet JB, et al. PEPCOL: A GERCOR randomized phase II study of nanoliposomal irinotecan PEP 02 (MM ‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer. Cancer Med  2016; 5(4): 676-83.
 [http://dx.doi.org/10.1002/cam4.635] [PMID:  26806397]

[165]
Tian X, Nguyen M, Foote HP, et al. CRLX101, a nanoparticle– drug conjugate containing camptothecin, improves rectal cancer chemoradiotherapy by inhibiting DNA repair and hif1α. Cancer Res  2017; 77(1): 112-22.
 [http://dx.doi.org/10.1158/0008-5472.CAN-15-2951] [PMID:  27784746]

[166]
Alabi C, Vegas A, Anderson D. Attacking the genome: Emerging siRNA nanocarriers from concept to clinic. Curr Opin Pharmacol  2012; 12(4): 427-33.
 [http://dx.doi.org/10.1016/j.coph.2012.05.004] [PMID:  22726555]

[167]
Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer  2009; 9(3): 153-66.
 [http://dx.doi.org/10.1038/nrc2602] [PMID:  19238148]

[168]
Lyon PC, Griffiths LF, Lee J, et al. Clinical trial protocol for TARDOX: A phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (Thermo-Dox®) using focused ultrasound in patients with liver tumours. J Ther Ultrasound  2017; 5(1): 28.
 [http://dx.doi.org/10.1186/s40349-017-0104-0] [PMID:  29118984]

[169]
Golan T, Grenader T, Ohana P, et al. Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: A phase 1 study in advanced solid tumor patients. Cancer Med  2015; 4(10): 1472-83.
 [http://dx.doi.org/10.1002/cam4.491] [PMID:  26172205]

[170]
Ishida T, Huang CL, Wada H. Inventors; delta fly pharma inc, assignee. Liposome containing shRNA molecule targeting a thymidylate synthase and use thereof US 8,592,572, 2013.

[171]
Xunjin ZH, Wong WK, Fengshou WU. Conjugated porphyrin carbon quantum dots for targeted photodynamic therapy Hong Kong Baptist University HKBU United States patent. US 10369221, 2019.

[172]
Cabeza L, Perazzoli G, Mesas C, et al. Nanoparticles in colorectal cancer therapy: Latest in vivo assays, clinical trials, and patents. AAPS PharmSciTech  2020; 21(5): 178.
 [http://dx.doi.org/10.1208/s12249-020-01731-y] [PMID:  32591920]

[173]
Mármol I, Sánchez-de-Diego C, Dieste AP, Cerrada E, Yoldi MJR. Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci  2017; 18(1): 197.
 [http://dx.doi.org/10.3390/ijms18010197] [PMID:  28106826]

[174]
Patelli G, Tosi F, Amatu A, et al. Strategies to tackle RAS-mutated metastatic colorectal cancer. ESMO Open  2021; 6(3): 100156.
 [http://dx.doi.org/10.1016/j.esmoop.2021.100156] [PMID:  34044286]

[175]
Xu T, Wang X, Xin Y, et al. Trastuzumab combined with irinotecan in patients with her2-positive metastatic colorectal cancer: A phase ii single-arm study and exploratory biomarker analysis. Cancer Res Treat  2023; 55(2): 626-35.
 [http://dx.doi.org/10.4143/crt.2022.1058] [PMID:  36550683]

[176]
Brar B, Ranjan K, Palria A, et al. Nanotechnology in colorectal cancer for precision diagnosis and therapy. Frontiers in Nanotechnology  2021; 3: 699266.
 [http://dx.doi.org/10.3389/fnano.2021.699266]
Rights & Permissions Print Cite
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/0126673878301004240703073107	Print ISSN 2667-3878
Publisher Name Bentham Science Publisher	Online ISSN 2667-3886
Recent Advances in Drug Delivery and Formulation

Functionalised Ligand-Based Nanomaterial Drug Targeting Approaches for Colorectal Cancer Therapy

Abstract Play Pause

Related Journals

Related Books

Abstract
